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Objective: To examined the impact of reproductive factors on the relationship between radiation treat-
ment (RT) for a first breast cancer and risk of contralateral breast cancer (CBC).
Methods: The Women’s Environmental Cancer and Radiation Epidemiology (WECARE) Study is a multi-
center, population-based case-control study where cases are women with asynchronous CBC (N ¼ 1521)
and controls are women with unilateral breast cancer (N ¼ 2211). Rate ratios (RR) and 95% confidence
intervals (CI) were estimated using conditional logistic regression to assess the independent and joint
effects of RT (ever/never and location-specific stray radiation dose to the contralateral breast [0, >0-
<1Gy, 1Gy]) and reproductive factors (e.g., parity).
Results: Nulliparous women treated with RT (1Gy dose) were at increased risk of CBC compared with
nulliparous women not treated with RT, although this relationship did not reach statistical significanceralateral breast cancer; Gy, Gray; NCI, National Cancer Institute; RT, Radiation treatment; RR, Rate ratio; SEER, Sur-
ral breast cancer; WECARE, Women’s Environmental Cancer and Radiation Epidemiology.
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WECARE Study(RR ¼ 1.34, 95% CI 0.87, 2.07). Women treated with RT who had an interval pregnancy (i.e., pregnancy
after first diagnosis and before second diagnosis [in cases]/reference date [in controls]) had an increased
risk of CBC compared with those who had an interval pregnancy with no RT (RR ¼ 4.60, 95% CI 1.16,
18.28). This was most apparent for women with higher radiation doses to the contralateral breast.
Conclusion: Among young female survivors of breast cancer, we found some evidence suggesting that
having an interval pregnancy could increase a woman’s risk of CBC following RT for a first breast cancer.
While sampling variability precludes strong interpretations, these findings suggest a role for pregnancy
and hormonal factors in radiation-associated CBC.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Exposure to ionizing radiation is an established breast cancer
risk factor that is influenced by age at exposure, absorbed dose, and
time since exposure [1,2]. Periods of rapid breast development (e.g.,
puberty) or differentiation (e.g., pregnancy) are times when the
breast may be more susceptible to the carcinogenic effects of ra-
diation [3e7], although results have been mixed [8].
Younger age at menarche and fewer full-term pregnancies are
established risk factors for both first [9] and second [10] primary
breast cancer. Womenwho have a first full-term pregnancy prior to
age 30 years are at reduced risk of a first primary breast cancer
compared to those who are nulliparous, and this risk is further
reduced with subsequent births. There is, however, an initial
transient increase in breast cancer risk for about 20 years following
a pregnancy, which thereafter is followed by a lower risk when
compared to nulliparous women [11].
The Women’s Environmental Cancer and Radiation Epidemi-
ology (WECARE) Study is a multi-centered, population-based case-
control study of young women (under age 55 years at first breast
cancer diagnosis). We previously reported that, among women
whose first breast cancer was diagnosed under age 40 years those
receiving at least 1.0 Gy (Gy) of absorbed radiation dose to the
contralateral breast during radiation treatment (RT) had a higher
risk of developing CBC (RR ¼ 2.5, 95% CI 1.4e4.5) than women not
receiving RT [12]. We have also shown that women who were
nulliparous and exposed to at least 1 Gy to the contralateral breast,
or who had a full-term pregnancy after RT for a first breast cancer,
were at increased risk of CBC [13]. However, the interpretation of
these latter findings was limited by small numbers. The second
phase of WECARE Study recruitment was recently completed,
effectively doubling our sample size. Here, we present results from
a combined analysis examining the joint effects of reproductive
factors and RT for a first breast cancer on risk of CBC.
2. Materials and methods
2.1. Study population
The WECARE Study is a multi-center, population-based case-
control study where cases are women with asynchronous CBC
and controls are women with unilateral breast cancer (UBC). Case-
control recruitment for the WECARE Study was conducted in two
phases: WECARE I (2001e2004) and WECARE II (2009e2012).
Participants were identified through eight population-based cancer
registries: Los Angeles County Cancer Surveillance Program; Cancer
Surveillance System of the Fred Hutchinson Cancer Research Center
(Seattle, WA); State Health Registry of Iowa; The Cancer Surveil-
lance Program of Orange County/San Diego-Imperial Organization
for Cancer Control (Orange County/San Diego, CA); the Greater Bay
Area Cancer Registry (San Francisco Bay Area Region and Santa
Clara Region, CA); and the Sacramento and Sierra Center Registries(Sacramento Region, CA). These cancer registries all contribute to
the National Cancer Institute (NCI) Surveillance, Epidemiology and
End Results (SEER) program in the US. Participants were also
recruited from the Ontario Cancer Registry and the Danish Breast
Cancer Cooperative Group Registry, supplemented by data from the
Danish Cancer Registry. All study participants provided written
informed consent and the study protocol was reviewed and
approved by the institutional review board at each site. Across all
cancer registries, 2354 CBC cases and 3599 UBC controls were
identified as eligible and were approached for the study. The
number of participants who completed the interview was 1521
cases and 2212 controls. Reasons for non-participation have been
described in detail [14].
Details of recruitment procedures and eligibility have been
described previously, and were nearly identical for the two study
phases [15,16]. Briefly, all women were diagnosed prior to age 55
years, between 1985 and 2008 with a first primary invasive breast
cancer (stage I-III). Cases were diagnosed with a second primary
CBC (in situ or invasive for WECARE I and invasive only for WECARE
II) at least one year later. Controls also had no history of any second
cancer diagnosis up to their reference date. The reference date for
cases was the CBC diagnosis date, while for controls it was defined
by adding the interval between the first breast cancer and the CBC
for the matched case, to the date of breast cancer diagnosis for the
control. Cases must also have been living in the same cancer
ascertainment area for both diagnoses, while controls were
required to be living in their matched case’s cancer ascertainment
areawhen their breast cancer was diagnosed and on their reference
date. Additionally, controls must not have undergone prophylactic
mastectomy of the unaffected contralateral breast. Study eligibility
was restricted to women who were alive, able to be contacted,
provide informed consent, complete a telephone interview, and
donate a blood or saliva sample for DNA extraction.
Controls were matched to cases (2:1 for WECARE I and 1:1 for
WECARE II) on year of birth in 5-year strata, year of diagnosis in 4-
year strata, cancer registry region, and race/ethnicity. In WECARE I,
cases and controls were further counter-matched based on cancer
registry-reported RT such that two members of each case-control
trio had received RT for their first breast cancer and the third
member had not [15]. Counter-matching was not used in Phase II;
this was taken into account in all statistical analyses, as detailed
below.
2.2. Data collection
WECARE Study participants were interviewed by telephone
using a structured questionnaire that was designed to obtain in-
formation about events occurring before the diagnosis of the first
primary breast cancer, as well as events that occurred after the first
diagnosis during the at-risk period. The at-risk period was defined
as beginning at least one year after diagnosis with a first breast
cancer and ending at the second diagnosis in CBC cases, or the
Table 1
Characteristics of women in the WECARE study, 1985e2008.
Variable CBC Cases
(N ¼ 1521)
UBC Controls
(N ¼ 2211)
Median Range Median Range
Age at first diagnosis (years) 46 24e54 46 23e54
Age at reference date (years)a 53 27e73 52 27e71
Length of at-risk period (years)b 6.3 1.0e19.8 5.6 1.0e19.8
N (%)c N (%)c
WECARE Study Phase
WECARE I 708 (47) 1399 (63)
WECARE II 813 (53) 812 (37)
Study area
Californiad 658 (43) 966 (44)
Canadae 159 (10) 157 (7)
Denmarkf 279 (18) 457 (21)
Iowag 201 (13) 314 (14)
Seattleh 224 (15) 317 (14)
Year of first breast cancer
1985e1988 238 (16) 467 (21)
1989e1992 415 (27) 647 (29)
1993e1996 427 (28) 631 (29)
1997e2008 441 (29) 466 (21)
Race/ethnicity
Non-Hispanic White 1335 (88) 1977 (89)
Hispanic White 69 (5) 93 (4)
Black 55 (4) 76 (3)
Asian or Other 62 (4) 65 (3)
Histology of first breast cancer
Ductal 1205 (79) 1772 (80)
Lobular 179 (12) 222 (10)
Medullary 51 (3) 65 (3)
Tubular/mucinous 42 (3) 80 (4)
Other 40 (3) 68 (3)
Unknown 4 (0) 4 (0)
Stage of first breast cancer
Local 1061 (70) 1442 (65)
Regional 448 (29) 758 (34)
Unknown 12 (1) 11 (1)
Chemotherapy for first breast cancer
No 699 (46) 923 (42)
Yes 822 (54) 1288 (58)
Radiation treatment for first breast canceri
WECARE I
No 362 (51) 266 (50)
Yes 346 (49) 1133 (50)
WECARE II
No 279 (34) 256 (32)
Yes 534 (66) 556 (68)
Hormone treatment for first breast cancer
No hormonal therapy 963 (63) 1270 (57)
Tamoxifen <5 years 279 (18) 466 (21)
Tamoxifen 5 years 119 (8) 184 (8)
Tamoxifen unknown duration 69 (5) 136 (6)
Other or unknown hormonal therapy 91 (6) 155 (7)
Abbreviations: CBC: contralateral breast cancer; N: Number; ER: estrogen receptor;
PR: progesterone receptor; UBC: unilateral breast cancer; WECARE Study: Women’s
Environmental Cancer and Radiation Epidemiology Study.
a Reference date is defined as the date of CBC diagnosis in cases and the corre-
sponding date in matched controls. This is determined by adding the time between
the two breast cancer diagnoses in the matched case to the date of the first breast
cancer diagnosis in the control.
b The time between a case’s first breast cancer and her CBC defined at-risk period.
For a matched control, her case’s at-risk period was added to the control’s date of
UBC and the date on which the at-risk period ended defined her reference date.
c Percentages may not sum to 100% due to rounding.
d Four study centers were included: 1) Los Angeles County Cancer Surveillance
Program, 2) The Cancer Surveillance Program of Orange County/San Diego-Imperial
Organization for Cancer Control, 3) Greater Bay Area Cancer Registry (San Francisco
Bay Area Region and Santa Clara Region), and 4) Sacramento and Sierra Center
Registries (Sacramento Region).
e The Ontario Cancer Registry.
f The Danish Breast Cancer Cooperative Group Database supplemented by the
Danish Cancer Registry.
g The State Health Registry of Iowa.
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tionnaire included questions about personal demographics, medi-
cal history, family and reproductive history, hormone use, body
size, smoking status, and alcohol intake. Additionally, medical re-
cords, pathology reports, and radiotherapy charts were used to
collect detailed treatment information (i.e., chemotherapy, hor-
monal therapy, and radiation therapy) for the first primary breast
cancer, any recurrences experienced prior to the reference date,
and tumor characteristics of the first primary breast cancer. One
woman (UBC control) was excluded due to missing information on
RT status. Location-specific dose to the contralateral breast from
stray radiation experienced during RT of a first primary breast
cancer was estimated as described previously [12]. Specifically,
radiation doses to the contralateral breast for each quadrant and
the areolar region were estimated and the dose received in the
quadrant of the breast where the case’s CBC occurred was assigned
to the case, and the dose received in the corresponding region of
the unaffected breast of each matched control was assigned to her
control(s). Dose estimates were available for 1324 cases and 1918
controls.
2.3. Statistical analysis
Rate ratios (RR) and 95% confidence intervals (CI) were esti-
mated, fitting multivariable conditional logistic regression models,
including known risk factors for CBC. The independent and joint
effects of RT and reproductive factors at first diagnosis and at
reference date were examined using a joint effects model [17]. We
examined the joint effects of RT (ever/never and location-specific
dose: 0, <1Gy and 1Gy) and menopausal status/age at meno-
pause, change in menopausal status between first diagnosis and
reference date, nulliparity, number of full-term pregnancies, full-
term pregnancy between first diagnosis and reference date (inter-
val pregnancy), full-term pregnancy in the two years prior to first
diagnosis, and history of breastfeeding. Because treatment for a
first breast cancer could inducemenopause, menopausal status and
age at menopause two years prior to first diagnosis were used.
Analyses examining the impact of having an interval pregnancy on
risk of CBC were restricted to women who were premenopausal
one year after first breast cancer diagnosis. Models were adjusted
for age at first diagnosis, histology, stage, first-degree family history
of breast cancer, age at menarche, age at menopause, use of
menopausal hormone therapy up to first diagnosis, and chemo-
therapy and hormonal therapy for first breast cancer. To take into
account the duration of hormonal therapy, the hormonal treatment
variable was coded as: no hormonal therapy, tamoxifen <5 years,
tamoxifen 5 years, tamoxifen unknown duration, other hormonal
therapy, unknown. We also examined the association between RT
and risk of CBC stratified by categories of each reproductive factor,
and report p-values for heterogeneity across these categories. P-
values for heterogeneity were estimated using nested likelihood
ratio tests. All statistical analyses were conducted using SAS 9.4
(SAS Institute Inc., Cary NC).
3. Results
Table 1 shows selected characteristics of the WECARE Study
population. Cases and controls had a median age at diagnosis of 46
years, with a median time between first and second breast cancer
diagnosis (first diagnosis and reference date in controls) of 6.3 years
in cases and 5.6 years in controls.
Women who were postmenopausal at first diagnosis and
reference date or who became postmenopausal during the at-risk
period were at a higher risk of CBC than those who remained
premenopausal throughout the study period. When we examined
h Cancer Surveillance System of the Fred Hutchinson Cancer Research Center.
i Proportion of individuals treated and not treated with radiation. In WECARE I,
cases and controls were counter-matched based on cancer registry reported radi-
ation treatment such that two members of each case-control trio had received ra-
diation treatment for their first breast cancer diagnosis. Proportions for controls in
WECARE I are weighted to reflect this selection. Proportions for cases in WECARE I
(because all cases were included) and both cases and controls inWECARE II (because
counter-matching was not used in WECARE II) are not weighted.
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RTand risk of CBC, there was some indication of an increased risk in
women who received RT and had become menopausal within 5-
<10 years of first diagnosis (RR ¼ 1.69, 95% CI 0.91, 3.13) compared
to premenopausal women who did not receive RT (Table 2). How-
ever, menopausal status did not modify the overall association
between RT status and risk of CBC (Tables 2 and 3). Further, while
the association between RT and risk of CBC was somewhat elevated
in nulliparous women receiving 1Gy radiation dose to the
contralateral breast compared to nulliparous women not treated
with RT, this association was not statistically significant (RR ¼ 1.34,
95% CI 0.87, 2.07) (Table 3).
Women who were treated with RT (ever/never) and had an in-
terval pregnancy (i.e., pregnancy between first diagnosis and
reference date) had a 4-fold higher risk of CBC (RR ¼ 4.60, 95% CI
1.16, 18.28) compared to those who had an interval pregnancy and
were not treated with RT (Table 2). When the impact of RT dose on
the relationship between interval pregnancy and risk of CBC was
examined, a significant positive dose-responsewas observed (ptrend
across dose categories ¼ 0.02). Compared to women who had an
interval pregnancy and were not treated with RT, the risk of CBC
increased non-significantly in women with >0-<1Gy dose to the
contralateral breast (RR ¼ 5.55, 95% CI 0.81, 38.10) and was signif-
icantly 12-fold higher for those with1Gy dose to the contralateral
breast (RR¼ 11.97, 95% CI 1.24,116) (Table 3). RT-associated CBC risk
was not modified by any of the other reproductive factors
examined.
We also examined the timeline of diagnoses, treatments
received for a first breast cancer and pregnancies for the 43 women
(18 cases and 25 controls) with an interval pregnancy. The average
age of diagnosis of these women was 31 years, with cases being
slightly younger than controls (30 versus 32 years respectively).
Cases were also younger at age at interval pregnancy (33 years for
cases and 36 years for controls), with a slightly larger proportion of
interval pregnancies being a first pregnancy for cases (56%) than
controls (52%). We found that the average time between first breast
cancer diagnosis and interval pregnancy was 2.7 years (range 0e8
years) for cases (3.5 for cases who did not receive RT and 2.3 for
those that did receive RT) and 4.0 (range 0e12 years) for controls
(4.7 for controls who did not receive RT and 3.6 for controls that
did).
Overall, among women who had a pregnancy in the two years
prior to first breast cancer diagnosis, compared to women who did
not receive RT for a first breast cancer, we did not find a significant
association between RT (ever/never) and risk of CBC amongwomen
(RR ¼ 1.58, 95% CI 0.68, 3.69) (Table 2) Whenwe looked at RT dose,
compared to women with a recent pregnancy prior to diagnosis
who did not receive RT, a non-statistically significant increase in
risk was observed in women at both dose levels (RR ¼ 1.31, 95% CI
0.49, 3.51 for women with >0-<1Gy dose to the contralateral
breast, and RR¼ 2.21, 95% CI 0.77, 6.35 for womenwith1Gy; ptrend
across dose categories ¼ 0.15) (Table 3).
4. Discussion
Women who were nulliparous at the time of first breast cancer
diagnosis and exposed to at least 1 Gy to the contralateral breastwhere at an increased risk of CBC, however this finding was not
statistically significant (RR ¼ 1.34, 95% CI 0.87, 2.07). We also
examined the impact of having a pregnancy around the time of RT
(before or after) and risk of CBC. When we looked at women who
had pregnancy following a first breast cancer diagnosis (i.e., inter-
val pregnancy), we found an increased risk in women treated with
RT compared to those that were not (RR ¼ 4.60, 95% CI 1.16, 18.28).
Overall, we did not find a significant association for pregnancy in
the two years prior to first diagnosis, and while the RR increased
with RT dose, the trend was not significant (ptrend ¼ 0.15).
We previously reported that women who were nulliparous and
exposed to at least 1 Gy to the contralateral breast had a 2-fold
increased risk of CBC, and that women with an interval preg-
nancy treated with RT had a 6-fold higher risk of CBC (RR ¼ 6.0 95%
CI 1.3, 28.4) [13]. The current study, with nearly double the sample
size, provides estimates that are somewhat attenuated with nar-
rower (but still wide) confidence intervals. In this initial analysis we
also had insufficient numbers to examine the impact of interval
pregnancy by dose to the contralateral breast. In the current study
with nearly doubled the sample size, interval pregnancies
remained a rare occurrence (12 cases and 15 controls treated with
RTand 6 cases and 10 controls not treatedwith RT). Still, we found a
significant positive dose effect (ptrend ¼ 0.02) associated with
having an interval pregnancy after RT. The risk of CBCwas about 12-
fold higher in the highest dose group, compared to womenwith an
interval pregnancy who did not receive RT. These risk estimates are
likely to be somewhat inflated due to the small number of events
and the lower risk of CBC observed in those who had an interval
pregnancy who were not treated with RT (RR ¼ 0.30, 95% CI, 0.08,
1.06). The factors driving this reduced risk are not clear.While these
risk estimates must be interpreted with caution, the potential
impact of having a pregnancy after treatment with RT for a first
breast cancer diagnosis on risk of CBC should not be dismissed.
When we further examined the characteristics of women who
had an interval pregnancy, we found that cases tended to be
younger at both first breast cancer diagnosis and interval preg-
nancy. Further, while both cases and controls who received RT for
their first breast cancer had pregnancies closer to first diagnosis
than those who did not, the timing was closest for cases (2.3 years
between first diagnosis and interval pregnancy for cases versus 3.6
years for controls).
Studies examining the impact of exposure to diagnostic or
therapeutic radiation (e.g., treatment for tuberculosis, mastitis or
Hodgkin’s lymphoma) at a young age (around the time of first
menses) [3,18e20], or while pregnant or lactating [3,4,21] have
found an increased risk of radiation-associated breast cancer (also
reviewed in Refs. [2]). The mechanism underlying this impact of
interval pregnancy following RT on risk of CBC is unknown but
could be related to changes in the breast that occur during and
directly following pregnancy. A “dual effect” of pregnancy is
observed with respect to risk of a first breast cancer. An initial in-
crease in risk of breast cancer is seen immediately following
pregnancy. This increase peaks around 5 years after childbirth and
persists for about 20 years, at which point the risk becomes lower
than that observed for nulliparous women [11]. It has been sug-
gested that the increased hormone levels experienced during
pregnancy could lead to the clonal expansion of previously initiated
cells in the breast [22,23]. Other possible mechanisms underlying
this initial increase in risk have been proposed, including a tumor
promoting microenvironment associated with tissue re-modelling
during post-partum involution, inflammation, and changes to the
immune system following pregnancy [24]. To capture the potential
impact of RT during a post-pregnancy, post-lactation, period of
involutional change, we examined the relationship between having
a pregnancy in the two years prior to first breast cancer diagnosis
Table 2
Joint effect of radiation treatment for first breast cancer (ever/never), reproductive factors and risk of CBC. Abbreviations: CBC: contralateral breast cancer, UBC: unilateral
breast cancer, RR: rate ratio, CI: confidence interval.
Radiation Treatment CBC
Cases
N (%)a
UBC
Controls
N (%)a
RR (95% CI)b,c RR (95% CI)c,d p-hete
Menopausal Status
Menopausal status/age at menopause (first diagnosis)
Premenopausal Never 467 (30.9) 382 (17.4) 1.00 1.00 0.92
Ever 657 (43.4) 1293 (58.9) 1.04 (0.88e1.23) 1.04 (0.88, 1.23)
Postmenopausal < 45 years Never 86 (5.7) 72 (3.3) 0.96 (0.65e1.40) 1.00
Ever 109 (7.2) 210 (9.6) 1.09 (0.81e1.48) 1.14 (0.75, 1.74)
Postmenopausal  45 years Never 84 (5.6) 64 (2.9) 1.17 (0.78e1.74) 1.00
Ever 110 (7.3) 176 (8.0) 1.24 (0.89e1.74) 1.07 (0.70, 1.64)
Menopausal status between first diagnosis and reference datef
Premenopausal throughout Never 79 (5.2) 73 (3.3) 1.00 1.00 0.81
Ever 111 (7.3) 312 (14.2) 0.94 (0.62e1.41) 0.94 (0.62, 1.41)
Pre- to post-menopausal Never 388 (25.6) 309 (14.1) 1.56 (1.05e2.34) 1.00
Ever 546 (36.1) 981 (44.7) 1.70 (1.16e2.50) 1.09 (0.90, 1.31)
Postmenopausal throughout Never 170 (11.2) 136 (6.2) 1.63 (1.03e2.59) 1.00
Ever 219 (14.5) 386 (17.6) 1.75 (1.14e2.69) 1.08 (0.80, 1.45)
Years since menopause (at first diagnosis)
Premenopausal Never 467 (30.9) 382 (17.4) 1.00 1.00 0.42
Ever 657 (43.4) 1293 (58.9) 1.04 (0.88e1.22) 1.04 (0.88e1.22)
Postmenopausal <5 years Never 76 (5.0) 51 (2.3) 1.24 (0.80e1.88) 1.00
Ever 102 (6.7) 163 (7.4) 1.09 (0.78e1.52) 0.88 (0.56e1.40)
Postmenopausal 5 - <10 years Never 42 (2.8) 41 (1.9) 0.85 (0.50e1.43) 1.00
Ever 57 (3.8) 97 (4.4) 1.43 (0.95e2.16) 1.69 (0.91e3.13)
Postmenopausal  10 years Never 52 (3.4) 44 (2.0) 0.96 (0.60e1.52) 1.00
Ever 60 (4.0) 126 (5.7) 1.02 (0.70e1.50) 1.07 (0.63e1.84)
Parity
Nulliparity (first diagnosis)
Yes Never 124 (8.2) 100 (4.5) 1.00 1.00 0.50
Ever 198 (13.1) 312 (14.1) 1.12 (0.79e1.57) 1.12 (0.79, 1.57)
No Never 514 (33.9) 422 (19.1) 0.96 (0.70e1.33) 1.00
Ever 680 (44.9) 1372 (62.2) 1.01 (0.74e1.36) 1.05 (0.89, 1.22)
Number of full-term pregnancies (first diagnosis)
None Never 124 (8.2) 100 (4.5) 1.00 1.00 0.86
Ever 198 (13.1) 312 (14.1) 1.11 (0.79e1.56) 1.11 (0.79, 1.56)
1 Never 108 (7.1) 80 (3.6) 1.10 (0.56e2.18) 1.00
Ever 163 (10.8) 260 (11.8) 1.25 (0.67e2.33) 1.13 (0.78, 1.65)
2 Never 406 (26.8) 342 (15.5) 1.00 (0.54e1.86) 1.00
Ever 517 (34.1) 1112 (50.4) 1.02 (0.55e1.89) 1.02 (0.8þ, 1.22)
Interval pregnancy (among premenopausal women at first diagnosis)g
No, parous at first diagnosis Never 180 (31.6) 115 (16.1) 1.00 1.00 0.10
Ever 240 (42.1) 422 (59.2) 0.99 (0.65e1.50) 0.99 (0.65, 1.50)
Yes, parous or nulliparous at first diagnosis Never 6 (1.1) 10 (1.4) 0.30 (0.08e1.06) 1.00
Ever 12 (2.1) 15 (2.1) 1.36 (0.49e3.82) 4.60 (1.16, 18.28)
No, nulliparous at first diagnosis Never 50 (8.8) 32 (4.5) 0.92 (0.38e2.21) 1.00
Ever 82 (14.4) 119 (16.7) 0.86 (0.45e1.66) 0.94 (0.42, 2.07)
Pregnancy in the 2 years prior to first diagnosis
No, parous at first diagnosis, no pregnancy 2 years prior to first diagnosis Never 497 (32.8) 405 (18.4) 1.00 1.00 0.52
Ever 643 (42.4) 1315 (59.6) 1.03 (0.88e1.21) 1.03 (0.88, 1.21)
Yes, pregnancy in the 2 years prior to first diagnosis Never 17 (1.1) 17 (0.8) 0.75 (0.36e1.56) 1.00
Ever 37 (2.4) 57 (2.6) 1.19 (0.72e1.97) 1.58 (0.68, 3.69)
No, nulliparous at first diagnosis Never 124 (8.2) 100 (4.5) 0.91 (0.64e1.29) 1.00
Ever 198 (13.1) 312 (14.1) 1.00 (0.76e1.33) 1.11 (0.78, 1.56)
a Frequency counts for factors do not sum to totals for cases and controls due to missing data.
b Joint-effects models, with reference group as unexposed for both radiation treatment and the reproductive factor of interest.
c Adjusted for age at first diagnosis, age at menarche, age at menopause (at first diagnosis for first diagnosis variables of interest and at reference date for reference date
variables of interest), histology at first diagnosis, breast cancer family history, stage at first diagnosis, chemotherapy, hormonal treatment/duration for first diagnosis, use of
menopausal hormone therapy up to first diagnosis, and mutual adjustment for reproductive factors of interest. A log-weight covariate was also included in each model to
account for the sampling probability of the counter-matching for radiation treatment status used inWECARE I. WECARE II participants (who were not counter-matched) were
assigned an offset term of 1.
d Stratified analyses examining the relationship between radiation treatment and risk of CBC by category of the different reproductive factors.
e p-value for heterogeneity of radiation treatment effect on risk of CBC across strata of reproductive variables and were estimated using a nested likelihood ratio test.
f Reference date is defined as the date of CBC diagnosis in cases and the corresponding date in matched controls. This is determined by adding the time between the two
breast cancer diagnoses in the matched case to the date of the first breast cancer diagnosis in the control.
g Restricted to women who were premenopausal 1 year after first breast cancer diagnosis (i.e., the start of the at-risk period).
J.D. Brooks et al. / The Breast 54 (2020) 62e6966and radiation-associated CBC. We found a non-significant risk in-
crease suggesting no major impact of RT during this time period in
relation to CBC risk.
Strengths of this study include the population-based design,
large study population, and detailed questionnaire and medicalrecord data. Importantly, we had location-specific estimates of RT
dose (in the quadrant where the CBC occurred), allowing for the
assessment of different doses of RT received by the contralateral
breast during treatment for a first primary breast cancer. However,
despite the large sample size and focus on young women,
Table 3
Joint effect of radiation treatment for first breast cancer (dose), reproductive factors and risk of CBC.
Radiation Dosea (Gy) CBC Cases
N (%)b
UBC Controls
N (%)b
RR (95% CI)c,d RR (95% CI)d,e p-hetf
Menopausal Status
Menopausal status/age at menopause (first diagnosis)
Premenopausal 0 396 (31.6) 321 (17.2) 1.00 1.00 0.21
>0-<1 269 (21.5) 601 (32.3) 0.96 (0.78e1.20) 0.96 (0.78e1.20)
1 252 (20.1) 494 (26.5) 1.04 (0.83e1.32) 1.04 (0.83e1.32)
Postmenopausal < 45 years 0 78 (6.2) 66 (3.5) 0.93 (0.63e1.38) 1.00
>0-<1 61 (4.9) 84 (4.5) 1.51 (0.99e2.31) 1.62 (0.97e2.70)
1 37 (3.0) 85 (4.6) 0.96 (0.59e1.56) 1.03 (0.59e1.80)
Postmenopausal  45 years 0 65 (5.2) 61 (3.3) 0.96 (0.63e1.48) 1.00
>0-<1 57 (4.5) 81 (4.4) 1.46 (0.93e2.29) 1.52 (0.89e2.57)
1 38 (3.0) 68 (3.7) 1.08 (0.65e1.79) 1.12 (0.63e2.01)
Menopausal status between first diagnosis and reference dateg
Premenopausal throughout 0 61 (4.9) 61 (3.3) 1.00 1.00 0.15
>0-<1 56 (4.5) 151 (8.1) 1.13 (0.69e1.84) 1.13 (0.69e1.84)
1 39 (3.1) 113 (6.1) 0.87 (0.51e1.49) 0.87 (0.51e1.49)
Pre-to post-menopausal 0 335 (26.7) 260 (14.0) 1.68 (1.10e2.57) 1.00
>0-<1 213 (17.0) 450 (24.2) 1.59 (1.03e2.45) 0.95 (0.74e1.21)
1 213 (17.0) 381 (20.5) 1.86 (1.20e2.88) 1.11 (0.86e1.44)
Postmenopausal throughout 0 143 (11.4) 127 (6.8) 1.56 (0.95e2.54) 1.00
>0-<1 118 (9.4) 165 (8.9) 2.38 (1.44e3.92) 1.53 (1.06e2.20)
1 75 (6.0) 153 (8.2) 1.65 (0.97e2.78) 1.06 (0.71e1.58)
Years since menopause (at first diagnosis)
Premenopausal 0 396 (31.6) 321 (17.2) 1.00 1.00 0.22
>0-<1 269 (21.5) 601 (32.3) 0.96 (0.77e1.19) 0.96 (0.77e1.19)
1 252 (20.1) 494 (26.5) 1.04 (0.82e1.31) 1.04 (0.82e1.31)
Postmenopausal <5 years 0 58 (4.6) 49 (2.6) 1.08 (0.69e1.68) 1.00
>0-<1 51 (4.1) 69 (3.7) 1.27 (0.80e2.03) 1.18 (0.66e2.10)
1 35 (2.8) 65 (3.5) 0.96 (0.57e1.60) 0.89 (0.48e1.63)
Postmenopausal 5 - <10 years 0 39 (3.1) 36 (1.9) 0.87 (0.51e1.50) 1.00
>0-<1 36 (2.9) 47 (2.5) 2.04 (1.17e3.53) 2.34 (1.13e4.85)
1 16 (1.3) 37 (2.0) 1.00 (0.50e2.00) 1.15 (0.50e2.65)
Postmenopausal  10 years 0 46 (3.7) 42 (2.3) 0.83 (0.52e1.33) 1.00
>0-<1 31 (2.5) 49 (2.6) 1.35 (0.78e2.32) 1.62 (0.84e3.14)
1 24 (1.9) 51 (2.7) 1.11 (0.60e2.02) 1.33 (0.65e2.72)
Parity
Nulliparity (first diagnosis)
Yes 0 109 (8.7) 88 (4.7) 1.00 1.00 0.36
>0-<1 88 (7.0) 154 (8.2) 1.06 (0.71e1.60) 1.06 (0.71e1.60)
1 76 (6.1) 111 (5.9) 1.34 (0.87e2.07) 1.34 (0.87e2.07)
No 0 430 (34.3) 364 (19.5) 0.96 (0.69e1.33) 1.00
>0-<1 299 (23.8) 613 (32.8) 1.07 (0.77e1.49) 1.12 (0.91e1.37)
1 253 (20.2) 538 (28.8) 0.97 (0.69e1.36) 1.01 (0.81e1.27)
Number of full-term pregnancies (first diagnosis)
None 0 109 (8.7) 88 (4.7) 1.00 1.00 0.59
>0-<1 88 (7.0) 154 (8.2) 1.07 (0.71e1.60) 1.07 (0.71e1.60)
1 76 (6.1) 111 (5.9) 1.33 (0.86e2.06) 1.33 (0.86e2.06)
1 0 90 (7.2) 69 (3.7) 0.86 (0.41e1.78) 1.00
>0-<1 76 (6.1) 112 (6.0) 1.17 (0.57e2.42) 1.37 (0.87e2.15)
1 62 (4.9) 106 (5.7) 1.04 (0.49e2.18) 1.21 (0.75e1.94)
2 0 340 (27.1) 295 (15.8) 0.85 (0.43e1.68) 1.00
>0-<1 223 (17.8) 501 (26.8) 0.91 (0.46e1.83) 1.07 (0.85e1.35)
1 191 (15.2) 432 (23.1) 0.82 (0.41e1.63) 0.96 (0.74e1.23)
Interval pregnancy (among premenopausal women at first diagnosis)h
No, parous at first diagnosis 0 144 (31.2) 99 (16.6) 1.00 1.00 0.11
>0-<1 105 (22.7) 194 (32.4) 0.71 (0.41e1.24) 0.71 (0.41e1.24)
1 87 (18.8) 158 (26.4) 1.12 (0.61e2.06) 1.12 (0.61e2.06)
Yes, parous or nulliparous at first diagnosis 0 4 (0.9) 9 (1.5) 0.19 (0.04e0.87) 1.00
>0-<1 6 (1.3) 8 (1.3) 1.04 (0.26e4.13) 5.55 (0.81e38.10)
1 5 (1.1) 3 (0.5) 2.24 (0.29e17.11) 11.97 (1.24e115.75)
No, nulliparous at first diagnosis 0 45 (9.7) 27 (4.5) 0.75 (0.33e1.74) 1.00
>0-<1 35 (7.6) 59 (9.9) 0.98 (0.43e2.24) 1.30 (0.55e3.06)
1 31 (6.7) 41 (6.9) 0.91 (0.37e2.21) 1.21 (0.46e3.14)
Pregnancy in the 2 years prior to first diagnosis
No, parous at first diagnosis 0 415 (33.1) 350 (18.7) 1.00 1.00 0.34
>0-<1 282 (22.5) 582 (31.2) 1.13 (0.92e1.38) 1.13 (0.92e1.38)
1 237 (18.9) 521 (27.9) 0.97 (0.78e1.23) 0.97 (0.78e1.23)
Yes, pregnancy in the 2 years prior to first diagnosis 0 15 (1.2) 14 (0.7) 0.80 (0.38e1.65) 1.00
>0-<1 17 (1.4) 31 (1.7) 1.04 (0.51e2.10) 1.31 (0.49e3.51)
1 16 (1.3) 17 (0.9) 1.76 (0.78e3.98) 2.21 (0.77e6.35)
No, nulliparous at first diagnosis 0 109 (8.7) 88 (4.7) 0.88 (0.62e1.27) 1.00
>0-<1 88 (7.0) 154 (8.2) 0.94 (0.66e1.35) 1.07 (0.71e1.60)
1 76 (6.1) 111 (5.9) 1.18 (0.79e1.75) 1.33 (0.86e2.06)
AbbreviationsCBC: contralateral breast cancer, UBC: unilateral breast cancer, RR: rate ratio, CI: confidence interval.
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a Location-specific radiation dose received in the quadrant of the breast where the CBC occurred for each case, and the corresponding region in the unaffected breast of her
matched control.
b Frequency counts for factors do not sum to totals for cases and controls due to missing data.
c Joint-effects models, with reference group as unexposed for both radiation treatment and the reproductive factor of interest.
d Adjusted for age at first diagnosis, age at menarche, age at menopause (at first diagnosis for first diagnosis variables of interest and at reference date for reference date
variables of interest), histology at first diagnosis, breast cancer family history, stage at first diagnosis, chemotherapy, hormonal treatment/duration for first diagnosis, use of
menopausal hormone therapy up to first diagnosis, and mutual adjustment for reproductive factors of interest. A log-weight covariate was also included in each model to
account for the sampling probability of the counter-matching for radiation treatment status used inWECARE I. WECARE II participants (who were not counter-matched) were
assigned an offset term of 1.
e Stratified analyses examining the relationship between radiation treatment and risk of CBC by category of the different reproductive factors.
f p-value for heterogeneity of radiation treatment effect on risk of CBC across strata of reproductive variables and were estimated using a nested likelihood ratio test.
g Reference date is defined as the date of CBC diagnosis in cases and the corresponding date in matched controls. This is determined by adding the time between the two
breast cancer diagnoses in the matched case to the date of the first breast cancer diagnosis in the control.
h Restricted to women who were premenopausal 1 year after first breast cancer diagnosis (i.e., the start of the at-risk period).
J.D. Brooks et al. / The Breast 54 (2020) 62e6968pregnancy following a first breast cancer diagnosis remained a
relatively rare occurrence in this study population. The median age
of the study population at first breast cancer diagnosis was 46 years
(784 [21%] were 40 years of age at first diagnosis), beyond
childbearing years for most women. This suggests the need to
examine the impact of an interval pregnancy after RT in women
with a very young age at first breast cancer diagnosis (i.e., prior to
40 years), notably cases with an interval pregnancy in this study
had two breast cancer diagnoses (UBC and CBC) prior to age 40
years. Women diagnosed at a very young age are also likely to have
a familial risk of breast cancer, which has been shown to further
increase the risk of breast cancer immediately following pregnancy
[11,25,26]. Finally, we examined the impact of multiple reproduc-
tive factors on the relationship between RT and risk of CBC. It is
possible therefore that any significant findings could be due to
chance.
There is increasing focus on the potential of patient-centered,
personalized treatment plans for women with breast cancer. As
the average five-year survival rate for a first primary breast cancer
is approaches 90% [27], there is a growing population of women
who have survived a first breast cancer diagnosis. This is extending
the use of a personalized approach to include survivorship [28].
Further, as more women continue to delay pregnancy, the number
of pregnancies that occur after a breast cancer diagnosis is likely to
increase. In the context of RT, this could include the decision to use
whole-breast radiation or accelerated partial breast radiation,
which would reduce the stray dose to the contralateral breast.
5. Conclusion
We found that women who were nulliparous at the time of RT
(1Gy dose to the contralateral breast) for a first breast cancer were
at an elevated risk of CBC, although this finding was not statistically
significant. Further, women who had a pregnancy after a first pri-
mary breast cancer diagnosis who were treated with RT, especially
those with higher doses to the contralateral breast, were at a sta-
tistically significant increased risk of CBC, although again results
were based on small numbers and the confidence intervals were
wide. While we are not able to make a strong statement for a
relationship between pregnancy around the time of RT and risk of
CBC, we are also not able to rule it out. These findings support the
need for continued investigation into this relationship, particularly
in young women with breast cancer for whom reproductive con-
cerns are important. National Comprehensive Cancer Network
(NCCN) guidelines currently recommend that patients do not get
pregnant during treatment (RT, chemotherapy, hormonal therapy)
or in the 6 months following completion of treatment with tras-
tuzumab or pertuzumab [29]. Further examination of the impact of
timing of pregnancy with respect to treatment and diagnosis is
needed. As the average five-year survival rate for a first primary
breast cancer approaches 90% [27], there is a growing population of
women at risk of CBC. Further, as more women continue to delaypregnancy, the number of pregnancies that occur after a breast
cancer diagnosis is likely to increase. Understanding the risks
associated with treatments received for a first breast cancer, and
how these may be modified by pregnancy, will inform discussions
between patients and their physicians, help guide future treatment
decisions and surveillance recommendations, and strengthen
evidence-based risk communication.
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